Glucagon Like Peptide 1 (7-36), amide (human) (GLP1)

Katalog-Nummer G2040-13P-1mg

Size : 1mg

Marke : US Biological

Weitere Informationen anfordern

Contact local distributor :


Telefonnummer : +1 850 650 7790


G2040-13P Glucagon Like Peptide 1 (7-36), amide (human) (GLP1)

Grade
Highly Purified
Shipping Temp
Blue Ice
Storage Temp
-20°C

GLP-1 is a incretion hormone, which has been shown to stimulate secretion of insulin in the presence of elevated blood glucose concentrations, but not during periods of low blood glucose concentrations (hypoglycemia). GLP-1 is released from gut endocrine cells in response to nutrient ingestion. The hormone is a physiologic mediator of satiety and regulates energy absorption and disposal. GLP-1 is an insulinotropic hormone that has the ability to render pancreatic beta cells glucose-competent. It has been used in the therapy of type-2 diabetes. GLP-1 has cytokine activity, although it is not classified as such due its small size GLP-1 enhances cell differentiation, plays a role in tissue regeneration, and mediates cytoprotection.

Description:
GLP-1 is a single, non-glycosylated, polypeptide chain containing 30 amino acids and having a molecular mass of 3.29kD. GLP-1 is a incretion hormone, which has been shown to stimulate secretion of insulin in the presence of elevated blood glucose concentrations, but not during periods of low blood glucose concentrations (hypoglycemia). GLP-1 is released from gut endocrine cells in response to nutrient ingestion. The hormone is a physiologic mediator of satiety and regulates energy absorption and disposal. GLP-1 is an insulinotropic hormone that has the ability to render pancreatic beta cells glucose-competent. It has been used in the therapy of type-2 diabetes. GLP-1 has activities of cyokines, although it is not classified as such due its small size GLP-1 enhances cell differentiation, plays a role in tissue regeneration, and mediates cytoprotection. GLP-1 is purified by proprietary chromatographic techniques.

Amino Acid Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be His-Ala-Glu-Gly-Thr.

Biological Activity:
1. Regulates Glucose levels rapidly
2. Reduces Insulin resistence
3. Reduces Glucagon
4. Reduces HbA1c
5. Stimulates beta cell grwoth which stimulates insulin production.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O to ≥0.1mg/ml. Add a carrier protein (0.1% HSA or BSA) for long term storage. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Applications
Source: E. coli|Purity: >95% by RP-HPLC and SDS-PAGE. Chromatographically purified.|Form: Supplied as a lyophilized powder without additives. Reconstitute in sterile ddH2O to ≥0.1mg/ml. Add 0.1% HSA or BSA for long term storage. This solution can then be diluted into other aqueous solutions.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a lyophilized powder without additives. Reconstitute in sterile ddH2O to ≥0.1mg/ml. Add 0.1% HSA or BSA for long term storage. This solution can then be diluted into other aqueous solutions.
Purity
>95% by RP-HPLC and SDS-PAGE. Chromatographically purified.
References
1. Glucagon-Like Peptide-1 Differentiation of Primate Embryonic Stem Cells into Insulin-Producing Cells. Tissue Eng 2006 Jun 1; 2. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.: Neuros ci Res Aug;55(4):352-60 (2006). 3. Glucagon and glucagon-like Peptide receptors as drug targets. Curr Pharm Des ;12(14):1731-50 (2006). 4. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol Jun;46(6):635-41 (2006). 5. From cradle to grave pancreatic beta-cell mass and glucagon-like peptide-1. Minerva Endocrinol Jun;31(2):107-24 (2006). 6. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. DiabetesMay;55(5):1484-90 (2006). .